US Pharma MarketingWhile a disappointing late-stage readout sent biotech stocks tumbling, all hope may not be lost for the emerging approach to treating cardiovascular events.
Did Novo’s phase 3 flop kill the inflammation hypothesis in heart disease?
While a disappointing late-stage readout sent biotech stocks tumbling, all hope may not be lost for the emerging approach to treating cardiovascular events.
Source: PharmaVoice